Business Wire

Verimatrix XTD Network Monitoring™ Enhances In-App Protection with Advanced Threat Detection

17.9.2024 17:45:00 CEST | Business Wire | Press release

Share

New feature provides comprehensive DNS cache analysis, phishing site monitoring, and malware command-and-control (C2) detection

Regulatory News:

Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced the general availability of its Verimatrix XTD Network Monitoring™ feature, expanding its suite of application cybersecurity solutions to combat evolving network-related threats.

Verimatrix XTD has long been at the forefront of identifying and neutralizing mobile app cyberthreats. The new Verimatrix XTD Network Monitoring™ feature builds on this expertise, offering advanced capabilities to detect and prevent communication with malicious servers. By performing in-depth DNS cache analysis, monitoring for phishing sites, and implementing malware command-and-control (C2) detection, Verimatrix XTD Network Monitoring™ provides a robust defense against sophisticated network attacks.

These features work together to protect users and their data from threats specific to smartphone applications. DNS cache analysis in this context involves examining the app's record of internet addresses of servers it has contacted, helping to identify if the app has communicated with potentially nefarious actors. Monitoring for phishing is crucial for mobile apps, especially those handling sensitive information like banking apps, as it helps detect and prevent the app from connecting to certain internet addresses that could potentially steal user credentials. Malware command-and-control (C2) detection for mobile apps focuses on detecting and preventing waves of attacks from devices that have been compromised to steal data and control applications. These security measures are particularly important for mobile apps because smartphones often contain a wealth of personal data and are frequently used for sensitive operations like online banking or shopping.

This new feature significantly enhances the protective measures available to Verimatrix customers, ensuring their networks remain secure against modern cyberthreats. By leveraging cutting-edge technology and Verimatrix's commitment to proactive security, Verimatrix XTD Network Monitoring™ offers a multi-layered approach to safeguarding critical network infrastructure and sensitive data.

"The ability to quickly identify and neutralize network-based threats is crucial," said Tom Powledge, Head of Cybersecurity Business for Verimatrix. "Verimatrix XTD Network Monitoring™ addresses this need by providing real-time detection of malicious activities, from phishing attempts to sophisticated malware communications. This feature provides mobile app developers and security teams with essential tools to enhance their application security protections and ensure regulatory compliance.”

Verimatrix XTD Network Monitoring™ seamlessly integrates with existing Verimatrix XTD services, offering a comprehensive security solution that addresses multiple aspects of application cybersecurity.

About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240917976957/en/

Contacts

Verimatrix Investor Contact:

Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
SEITOSEI.ACTIFIN
Mathilde Guillemot-Costes
mathilde.guillemot@seitosei-actifin.com
Michael Scholze
Michael.scholze@seitosei-actifin.comVerimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com

finance@verimatrix.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye